November 17, 2025- Thermo Fisher Scientific Inc. announced the enrollment of the first patient in the new PPD™ CorEvitas™ Myasthenia Gravis (MG) Registry. This nationwide registry will collect data from MG patients across the United States to study and evaluate existing and emerging MG therapies, tracking health conditions, safety issues, medication usage and overall treatment effectiveness. By leveraging real-world data, the registry will enhance the understanding of MG and improve patient care. The registry is designed to collect clinical data from enrolled patients under the care of a neurologist in both academic and private practice settings. The registry is now active in the U.S., with the first patient enrolled on November 10.
MG is a rare autoimmune disorder of the neuromuscular junction causing muscle weakness and fatigue that worsens with activity and may fluctuate daily. While more common in adults, MG can affect people of all ages, and the exact cause is unknown. It is estimated that over 70,000 people in the U.S. have been diagnosed with MG. Patients can experience a wide range of symptoms that can vary from mild to severe and may include periods of remission with no symptoms, severe episodes that worsen with daily activities, or myasthenic crisis, which involves severe muscle weakness affecting breathing or swallowing, requiring medical support such as intubation or ventilation. There’s currently no way to prevent or cure MG, but treatment can help manage symptoms.